How effective is nicotine replacement therapy in helping people to stop smoking?

OBJECTIVE--To assess the efficacy of nicotine replacement therapy in helping people to stop smoking. DESIGN--Analysis of the results of 28 randomised trials of nicotine 2 mg chewing gum, six trials of nicotine 4 mg chewing gum, and six trials of nicotine transdermal patch. SUBJECTS AND SETTING--Subjects were self referred (responding to advertisements or attending anti-smoking clinics) in 20 trials and invited (general practice or hospital patients) in 20. Therapists in self referred trials were generally experienced in helping people stop smoking but not in invited trials. MAIN OUTCOME MEASURE--Efficacy was defined as difference in percentages of treated and control subjects who had stopped smoking at one year. RESULTS--Efficacy was highly significant (P < 0.001) for both gum and patch. Nicotine 2 mg chewing gum had an overall efficacy of 6% (95% confidence interval 4% to 8%), greater in self referred subjects than in invited subjects (11% v 3%). Efficacy depended on the extent of dependence on nicotine as assessed by a simple questionnaire; it was 16% (7% to 25%) in "high dependence" smokers, but in "low dependence" smokers there was no significant effect. The 4 mg gum was effective in about one third of "high dependence" smokers. The efficacy of the nicotine patch (9% (6% to 13%) overall) was less strongly related to nicotine dependence, perhaps because the patch cannot deliver a bolus of nicotine to satisfy craving. CONCLUSIONS--Both gum and patch are effective aids to help nicotine dependent smokers who seek help in stopping. Among the most highly nicotine dependent smokers (those craving a cigarette on waking) the 4 mg gum is the most effective form of replacement therapy; it could enable one third to stop. In less highly dependent smokers the different preparations are comparable in their efficacy but the patch offers greater convenience and minimal need for instruction in its use. Overall, nicotine replacement therapy could enable about 15% of smokers who seek help in stopping smoking to give up the habit.     

聚焦色谱法测定肌型肌酸激酶亚型

报道了测定CK-MM亚型的聚焦色谱法,此法简单,快速,结果可靠,线性范围宽,最低检测限（8U／L）较正常参考值低,比国外报道的类似方法高6倍以上,分离度亦有改进.测定了20例健康人血清亚型分布,与文献报道结果相近.该法自动化程度高,已在急性心梗的诊断中实际应用.     

质体醌重组的D1／D2／Cytb559复合物的荧光衰减动力学和光破坏作用

光系统Ⅱ反应中心Ｄ１／Ｄ２／Ｃｙｔｂ５５９ 在分离纯化过程中失去了电子受体ＱＡ 和ＱＢ,人工合成的质体醌可以与Ｄ１／Ｄ２／Ｃｙｔｂ５５９ 复合物发生重组。癸基质体醌（ＤＰＱ）与Ｄ１／Ｄ２／Ｃｙｔｂ５９９ 复合物的重组导致该复合物的荧光强度下降及发射光谱蓝移,同时两个与光化学活性相关的长寿命（２４ ｎｓ和７３ ｎｓ）荧光衰减组分占整个荧光的百分数下降,这些结果表明ＤＰＱ作为Ｐｈｅｏ－ 的电子受体,限制了Ｐ６８０＋ ·Ｐｈｅｏ－ 的电荷重组。ＤＰＱ 的加入对Ｄ１／Ｄ２／Ｃｙｔｂ５５９复合物中Ｃｈｌａ 分子的光破坏敏感性影响不大,但β－胡萝卜素在加入ＤＰＱ 之后可以被光照破坏,这个过程可能与β－胡萝卜素的生理功能相关。     

田麻属的分类学研究

本文对田麻属植物的分类进行了研究,确认1种2变种,归并了1种3变种1变型,降级1种。     

人重组IL6／IL2融合蛋白的变性、复性及纯化

经超声破碎,分离已表达CH925包涵体,较系统地研究变性剂浓度、融合蛋白浓度对蛋白折叠的影响.在还原型及氧化型谷胱甘肽复性条件下,成功地将融合蛋白CH925折叠成具有IL6及IL2双活性蛋白,IL6的比活为2.3×10⁸U/mg, IL2比活为2.2×10⁶U/mg.经阴离子交换、凝胶过滤层析,获得一定纯度的CH925,配合反相HPLC.洗脱收集蛋白峰,CH925纯度为98%.     

RGDS肽对大鼠主动脉球囊内膜剥脱后血管壁增殖的影响

在大鼠主动脉球囊内膜剥脱术后血管壁细胞过度增殖模型上,用合成的血小板膜纤维蛋白原受体（ｇｌｙｃｏｐｒｏｔｅｉｎⅡｂ／Ⅲａｃｏｍｐｌｅｘ,ＧＰⅡｂ／Ⅲａ）拮抗剂ＲＧＤＳ（Ａｒｇ－Ｇｌｙ－Ａｓｐ－Ｓｅｒ,５０μｍｏｌ·ｋｇ－１·ｄ－１）治疗可有效地抑制损伤血管壁的细胞计数增加和内膜增厚以及血管平滑肌细胞增殖,显著降低其血管组织３Ｈ－ＴｄＲ和３Ｈ－Ｌｅｕ的参入增加程度。实验结果提示ＲＧＤＳ肽作为血管成型术的辅佐剂,对于防治血管再狭窄可能具有潜在的临床应用前景。     

重组人IL6／2融合蛋白对6.5Gy照射小鼠造血功能恢复的影响

观察了ｈＦＰＩＬ６／２对６．５Ｇｙγ线照射ＮＩＨ小鼠第１０天造血功能恢复的影响。结果表明：照射小鼠连续４ｄ给予ｈＦＰＩＬ６／２２５０μｇ·ｋｇ－１·ｄ－１,其脾重、ＣＦＵ－８、骨髓有核细胞数及ＣＭ－ＣＦＵ分别比对照组增加５９．０％、２７８．５％、５７．９％和１３８．２％,统计学处理均有显著差异;对此四项指标的改善也明显优于２５μｇ组。另外,２５０μｇ剂量组小鼠外周血象３０ｄ的动态观察结果表明,ｈＦＰＩＬ６／２不但能明显提高红细胞和血红蛋白的最低值,而且能使血小板的恢复提前。提示ｈＦＰＩＬ６／２在促进血小板生成和促进红系造血方面可能具有良好的应用前景。     

PCR和生物素探针对HFRSV的检测和分型的探讨

分析比较肾综合征出血热病毒（ＨＦＲＳＶ）７６／１１８株和Ｒ＿（２２）株的核苷酸序列,根据引物设计原则及检测分型的目的,设计并合成了３对引物。１对引物取于两毒株间的高同源区段,作为共同引物和外引物;另两对引物取于两毒株间的低同源区段,分别作为野鼠型引物、家鼠型引物和内引物。建立了ＤＮＡ聚合酶链反应（ＰＣＲ）和ＮｅｓｔＰＣＲ方法,并用ＮｃｓｔＰＣＲ合成了两种型特异的生物素探针。ＰＣＲ检测７６／１１８、Ａ＿９、陈、Ｒ＿２、Ｒ＿２２５个毒株,用外引物时均扩增出１条约３００ｂｐ的条带;用内引物的野鼠型引物时,除Ｒ＿（２２）株之外,其余４株均扩增出１条约７０ｂｐ的条带。斑点杂交试验证实了ＰＣＲ检测分型的准确性。ＮｅｓｔＰＣＲ和生物素探针斑点杂交试验可以测出１－１０ｂｇ的目的ｃＤＮＡ。     

植物雄性不育类型的分析

本文论述了植物雄性不育的类型、原因、诱导和应用,总结了国内外在这方面的研究成果。重点对植物雄性不育的类型给以分析,从而丰富了遗传多样性的内容,展示了雄性不育理论和应用研究的光明前景。